[1] Kaplan M, Gershwin M, 2005, Primary Biliary Cirrhosis. New England Journal of Medicine, 353(12): 1261–1273.

[2] Neuberger J, 2003, Liver Transplantation for Primary Biliary Cirrhosis. Autoimmunity Reviews, 2(1): 1–7.

[3] Bergasa N, 2005, The Pruritus of Cholestasis. Journal of Hepatology, 43(6): 1078–1088.

[4] Huet P, Deslauriers J, Tran A, et al., 2000, Impact of Fatigue on the Quality of Life of Patients with Primary Biliary Cirrhosis. The American Journal of Gastroenterology, 95(3): 760–767.

[5] Rishe E, Azarm A, Bergasa N, 2008, Itch in Primary Biliary Cirrhosis: A Patients’ Perspective. Acta Dermato-Venereologica, 88(1): 34–37.

[6] Carbone M, Nardi A, Flack S, et al., 2018, Pretreatment Prediction of Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis: Development and Validation of the UDCA Response Score. The Lancet Gastroenterology & Hepatology, 3(9): 626–634.

[7] Mayo M, Carey E, Smith H, et al., 2023, Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis. Digestive Diseases and Sciences, 68(3): 995–1005.

[8] Kirby J, Heaton K, Burton J, 1974, Pruritic Effect of Bile Salts. British Medical Journal, 4(5946): 693–695.

[9] Kode V, Yimam K, 2024, Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies. Current Hepatology Reports, 23: 123–136.

[10] Varadi D, 1974, Pruritus Induced by Crude Bile and Purified Bile Acids. Archives of Dermatology, 109(5): 678.

[11] Appleby R, Walters J, 2014, The Role of Bile Acids in Functional GI Disorders. Neurogastroenterology & Motility, 26(8): 1057–1069.

[12] Yu H, Zhao T, Liu S, et al., 2019, MRGPRX4 Is a Bile Acid Receptor for Human Cholestatic Itch. eLife, 8: e48431.

[13] Han L, Ma C, Liu Q, et al., 2013, A Subpopulation of Nociceptors Specifically Linked to Itch. Nature Neuroscience, 16(2): 174–182.

[14] Yu H, Wangensteen K, Deng T, Li Y, Luo W, 2021, MRGPRX4 in Cholestatic Pruritus. Seminars in Liver Disease, 41(3): 358–367.

[15] Meixiong J, Vasavda C, Snyder S, et al., 2019, MRGPRX4 Is a G Protein-Coupled Receptor Activated by Bile Acids That May Contribute to Cholestatic Pruritus. Proceedings of the National Academy of Sciences, 116(21): 10525–10530.

[16] Dawson P, Haywood J, Craddock A, et al., 2003, Targeted Deletion of the Ileal Bile Acid Transporter Eliminates Enterohepatic Cycling of Bile Acids in Mice. Journal of Biological Chemistry, 278(36): 33920–33927.

[17] Dilger K, Hohenester S, Winkler-Budenhofer U, et al., 2012, Effect of Ursodeoxycholic Acid on Bile Acid Profiles and Intestinal Detoxification Machinery in Primary Biliary Cirrhosis and Health. Journal of Hepatology, 57(1): 133–140.

[18] Trauner M, Boyer J, 2003, Bile Salt Transporters: Molecular Characterization, Function, and Regulation. Physiological Reviews, 83(2): 633–671..

[19] Banerjee A, Swaan P, 2006, Membrane Topology of Human ASBT (SLC10A2) Determined by Dual Label Epitope Insertion Scanning Mutagenesis: New Evidence for Seven Transmembrane Domains. Biochemistry, 45(3): 943–953.

[20] Zhang E, Phelps M, Banerjee A, et al., 2004, Topology Scanning and Putative Three-Dimensional Structure of the Extracellular Binding Domains of the Apical Sodium-Dependent Bile Acid Transporter (SLC10A2). Biochemistry, 43(36): 11380–11392.

[21] Hussainzada N, Claro T, Swaan P, 2009, The Cytosolic Half of Helix III Forms the Substrate Exit Route During Permeation Events of the Sodium/Bile Acid Cotransporter ASBT. Biochemistry, 48(36): 8528–8539.

[22] Lanzini A, Tavonatti M, Panarotto B, et al., 2003, Intestinal Absorption of the Bile Acid Analogue 75Se-Homocholic Acid-Taurine Is Increased in Primary Biliary Cirrhosis, and Reverts to Normal During Ursodeoxycholic Acid Administration. Gut, 52(9): 1371–1375.

[23] Cai S, Boyer J, 2021, The Role of Bile Acids in Cholestatic Liver Injury. Annals of Translational Medicine, 9(8): 737–737.

[24] Chen W, Wei Y, Xiong A, et al., 2019, Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. Clinical Reviews in Allergy & Immunology, 58(1): 25–38.

[25] Feng S, Xie X, Li J, et al., 2024, Bile Acids Induce Liver Fibrosis Through the NLRP3 Inflammasome Pathway and the Mechanism of FXR Inhibition of NLRP3 Activation. Hepatology International, 18(3): 1040–1052.

[26] Feng S, Xie X, Li J, et al., 2025, Correction: Bile Acids Induce Liver Fibrosis Through the NLRP3 Inflammasome Pathway and the Mechanism of FXR Inhibition of NLRP3 Activation. Hepatology International.

[27] PubChem, 2025, Linerixibat. PubChem Database, visited on April 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Linerixibat.

[28] Wu Y, Aquino C, Cowan D, et al., 2013, Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry, 56(12): 5094–5114.

[29] Hegade V, Bolier R, Elferink R, et al., 2016, A Systematic Approach to the Management of Cholestatic Pruritus in Primary Biliary Cirrhosis. Frontline Gastroenterology, 7(3): 158–166.

[30] Hegade V, Jones D, Hirschfield G, 2017, Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Digestive Diseases, 35(3): 267–274.

[31] Peppel I, Verkade H, Jonker J, 2020, Metabolic Consequences of Ileal Interruption of the Enterohepatic Circulation of Bile Acids. American Journal of Physiology – Gastrointestinal and Liver Physiology, 319(5): G619–G625.

[32] Zamek-Gliszczynski M, Kenworthy D, Bershas D, et al., 2021, Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers. Drug Metabolism and Disposition, 49(12): 1109–1117.

[33] Hegade V, Kendrick S, Dobbins R, et al., 2017, Effect of Ileal Bile Acid Transporter Inhibitor GSK2330672 on Pruritus in Primary Biliary Cholangitis: A Double-Blind, Randomised, Placebo-Controlled, Crossover, Phase 2a Study. Lancet, 389(10074): 1114–1123.

[34] Ino H, Endo A, Wakamatsu A, et al., 2018, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers. Clinical Pharmacology in Drug Development, 8(1): 70–77.

[35] Tanaka A, Atsukawa M, Tsuji K, et al., 2023, Japanese Subgroup Analysis of GLIMMER: A Global Phase IIb Study of Linerixibat for the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis. Hepatology Research, 53(7): 629–640.

[36] GlaxoSmithKline, 2024, Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (PBC), GSK Press Release, visited on April 14, 2025, https://www.gsk.com/en-gb/media/press-releases/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/.

[37] GlaxoSmithKline, 2025, Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN), visited on April 14, 2025, https://clinicaltrials.gov/study/NCT04950127.

[38] Ticho A, Malhotra P, Dudeja P, et al., 2019, Bile Acid Receptors and Gastrointestinal Functions. Liver Research, 3(1): 31–39.

[39] Davie R, Hosie K, Grobler S, et al., 1994, Ileal Bile Acid Malabsorption in Colonic Crohn’s Disease. British Journal of Surgery, 81(2): 289–290.

[40] Vítek L, 2015, Bile Acid Malabsorption in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 21(2): 476–483.

[41] Levy C, Kendrick S, Bowlus C, et al., 2023, GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus. Clinical Gastroenterology and Hepatology, 21(7): 1902–1912.

[42] Yi S, Kim I, Hager R, et al., 2024, FDA Approval Summary: Odevixibat (Bylvay) for the Treatment of Pruritus With Progressive Familial Intrahepatic Cholestasis. Gastro Hep Advances, 2024: 100596–100596.

[43] Graffner H, Gillberg P, Rikner L, et al., 2015, The Ileal Bile Acid Transporter Inhibitor A4250 Decreases Serum Bile Acids by Interrupting the Enterohepatic Circulation. Alimentary Pharmacology & Therapeutics, 43(2): 303–310.

[44] Shneider B, Spino C, Kamath B, et al., 2022, Impact of Long‐Term Administration of Maralixibat on Children With Cholestasis Secondary to Alagille Syndrome. Hepatology Communications, 6(8): 1922–1933.

[45] Loomes K, Squires R, Kelly D, et al., 2022, Maralixibat for the Treatment of PFIC: Long‐Term, IBAT Inhibition in an Open‐Label, Phase 2 Study. Hepatology Communications, 6(9): 2379–2390.

[46] Mayo M, Pockros P, Jones D, et al., 2019, A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatology Communications, 3(3): 365–381.

[47] Baghdasaryan A, Claudel T, Gumhold J, et al., 2011, Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2−/− (Abcb4−/−) Mouse Cholangiopathy Model by Promoting Biliary HCO₃⁻ Output. Hepatology, 54(4): 1303–1312.

[48] Inagaki T, Choi M, Moschetta A, et al., 2005, Fibroblast Growth Factor 15 Functions as an Enterohepatic Signal to Regulate Bile Acid Homeostasis. Cell Metabolism, 2(4): 217–225.

[49] Kim I, Ahn S, Inagaki T, et al., 2007, Differential Regulation of Bile Acid Homeostasis by the Farnesoid X Receptor in Liver and Intestine. Journal of Lipid Research, 48(12): 2664–2672.

[50] Casey J, Sly W, Shah G, et al., 2009, Bicarbonate Homeostasis in Excitable Tissues: Role of AE3 Cl−/HCO₃− Exchanger and Carbonic Anhydrase XIV Interaction. American Journal of Physiology-Cell Physiology, 297(5): 1091–1102.

[51] Hu Y, Liu X, Zhan W, 2018, Farnesoid X Receptor Agonist INT-767 Attenuates Liver Steatosis and Inflammation in Rat Model of Nonalcoholic Steatohepatitis. Drug Design, Development and Therapy, 12: 2213–2221.

[52] Kawamata Y, Fujii R, Hosoya M, et al., 2003, A G Protein-Coupled Receptor Responsive to Bile Acids. Journal of Biological Chemistry, 278(11): 9435–9440.

[53] Keitel V, Donner M, Winandy S, et al., 2008, Expression and Function of the Bile Acid Receptor TGR5 in Kupffer Cells. Biochemical and Biophysical Research Communications, 372(1): 78–84.

[54] Bunnett N, 2014, Neuro-Humoral Signalling by Bile Acids and the TGR5 Receptor in the Gastrointestinal Tract. The Journal of Physiology, 592(14): 2943–2950.

[55] Pols T, Nomura M, Harach T, et al., 2011, TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading. Cell Metabolism, 14(6): 747–757.

[56] Braadland PR, Schneider KM, Bergquist A, Molinaro A, Lövgren-Sandblom A, Henricsson M, Karlsen TH, Vesterhus M, Trautwein C, Hov JR, Marschall HU, 2022, Suppression of Bile Acid Synthesis as a Tipping Point in the Disease Course of Primary Sclerosing Cholangitis. JHEP Reports, 4(11): 100561.

[57] Escient Pharmaceuticals Inc, 2023, Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus, visited on April 14, 2025, https://clinicaltrials.gov/study/NCT04510090.

[58] Escient Pharmaceuticals, 2022, MRGPRX4-Targeted Therapeutics for Neurosensory-Inflammatory Disorders, visited on April 14, 2025, https://www.escientpharma.com/programs/mrgprx4/.